Alex Zhavoronkov (Insilico)

Weeks af­ter launch, Alex Zha­voronkov's AI-in­spired longevi­ty spin­out sells to Hong Kong-list­ed group

When Alex Zha­voronkov un­veiled In­sil­i­co’s longevi­ty-fo­cused spin­out, he kept the pre­cise amount of Se­ries A fund­ing un­der wraps — dis­clos­ing on­ly that it’s in the “few mil­lion” dol­lar range — but had its mar­quee syn­di­cate on full dis­play.

Hu­man Longevi­ty, a col­lab­o­ra­tor, co-led the round with ETP Ven­tures and Per­for­mance Im­pact Ven­ture Fund, flanked by BOLD Cap­i­tal Part­ners, Longevi­ty Vi­sion Fund, Ocu­lus co-founder Michael Antonov through Formic Ven­tures and LongeVC.

The line­up, along­side Deep Longevi­ty’s promise of of­fer­ing longevi­ty as a ser­vice, was ev­i­dent­ly suf­fi­cient to trig­ger a buy­out for Hong Kong-list­ed Re­gent Pa­cif­ic.

Zha­voronkov’s crew is bag­ging $3.79 mil­lion (HKD$29.56 mil­lion) from the takeover, which will see Deep Longevi­ty be­come a sub­sidiary of Re­gent Pa­cif­ic and a “core en­gine” of the longevi­ty ecosys­tem it’s look­ing to build. In an email to End­points News, Zha­voronkov not­ed that Re­gent Pa­cif­ic knows one of Deep Longevi­ty’s tar­get in­dus­try — in­sur­ance com­pa­nies — and as much as its in­ter­est sur­prised the team, the deal was too at­trac­tive to turn down.

A key con­nec­tion here was bil­lion­aire Jim Mel­lon, who’s board chair­man at both Re­gent Pa­cif­ic and Deep Longevi­ty (“we com­mon­ly re­fer to him as the ‘longevi­ty biotech­nol­o­gy Je­sus,'” Zha­voronkov wrote). A long be­liev­er in In­sil­i­co, he had in­vest­ed in Deep Longevi­ty and is work­ing with Wei-Wu He, the chair­man of Hu­man Longevi­ty and “the longevi­ty biotech­nol­o­gy Bud­dha,” on the board.

While Re­gent Pa­cif­ic’s pre­vi­ous in­vest­ments in the health­care, well­ness and life sci­ences sec­tors have tak­en it every­where from an EMA-ap­proved pre­ma­ture ejac­u­la­tion treat­ment to CBD e-com­merce, CEO Jamie Gib­son said the long-term vi­sion now is to trans­form in­to a “glob­al end-to-end longevi­ty and well­ness biotech­nol­o­gy com­pa­ny.”

“It is on­ly log­i­cal to start ex­e­cut­ing on this vi­sion via the ac­qui­si­tion of the most so­phis­ti­cat­ed ar­ti­fi­cial in­tel­li­gence sys­tem de­signed to track the rate of hu­man ag­ing and eval­u­ate the ef­fec­tive­ness of longevi­ty in­ter­ven­tions,” he said in a state­ment.

I can not com­ment on the ex­act as­sets and fore­casts for Re­gent Pa­cif­ic but I am con­fi­dent that the in­te­gra­tion and fu­ture of the com­pa­ny will be very ex­cit­ing and you are like­ly to be pos­i­tive­ly sur­prised more than once.

At its core, Deep Longevi­ty’s main of­fer­ing is a “deep ag­ing clock” that de­ter­mines a per­son’s true bi­o­log­i­cal age by in­te­grat­ing mul­ti­ple met­rics from blood tests, mi­cro­bio­me analy­sis as well as voice and imag­ing in­put in­to a neur­al net­work.

As the an­ti-ag­ing in­dus­try takes off, the idea is that be­ing able to pin­point why ex­act­ly some­one is ag­ing will be valu­able in­for­ma­tion to a broad swath of clients: longevi­ty and per­for­mance clin­ics, in­sur­ance com­pa­nies, phar­ma­ceu­ti­cal com­pa­nies, and even large em­ploy­ers with a work­force they’d like to re­tain.

“You can­not in­ter­vene if you can­not mea­sure,” Zha­voronkov, who’s dou­bling as CEO, told End­points News up­on launch.

The biotech spin­out draws from In­sil­i­co’s ex­per­tise in ar­ti­fi­cial in­tel­li­gence, a buzz­word that’s gar­nered both en­thu­si­asm and skep­ti­cism in an in­dus­try peren­ni­al­ly yearn­ing for short­er drug de­vel­op­ment time­lines.

With Zha­voronkov re­main­ing at the helm af­ter the Re­gent takeover, its ul­ti­mate goal is to de­vel­op a stan­dard-set­ting “longevi­ty cloud” — a set of both uni­ver­sal and ap­pli­ca­tion-spe­cif­ic bio­mark­ers of ag­ing, in­clud­ing some that “peo­ple did not pre­vi­ous­ly think about in the con­text of ag­ing clocks.”

“I hope to be able to talk about it soon,” he wrote.

Secretary of health and human services Alex Azar speaking in the Rose Garden at the White House (Photo: AFP)

Trump’s HHS claims ab­solute au­thor­i­ty over the FDA, clear­ing path to a vac­cine EUA

The top career staff at the FDA have vowed not to let politics get in the way of science when looking at vaccine data this fall. But Alex Azar, who happens to be their boss’s boss, apparently won’t even give them a chance to stand in the way.

In a new memorandum issued Tuesday last week, the HHS chief stripped health agencies under his purview — including the FDA — of their rulemaking ability, asserting all such power “is reserved to the Secretary.” Sheila Kaplan of the New York Times first obtained and reported the details of the September 15 bulletin.

Eli Lilly CSO Dan Skovronsky (file photo)

#ES­MO20: Eli Lil­ly shows off the da­ta for its Verzenio suc­cess. Was it worth $18 bil­lion?

The press release alone, devoid of any number except for the size of the trial, added nearly $20 billion to Eli Lilly’s market cap back in June. Now investors and oncologists will get to see if the data live up to the hype.

On Sunday at ESMO, Eli Lilly announced the full results for its Phase III MonarchE trial of Verzenio, showing that across over 5,000 women who had had HR+, HER2- breast cancer, the drug reduced the odds of recurrence by 25%. That meant 7.8% of the patients on the drug arm saw their cancers return within 2 years, compared with 11.3% on the placebo arm.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,300+ biopharma pros reading Endpoints daily — and it's free.

Dan Skovronsky, Eli Lilly CSO

UP­DAT­ED: An­a­lysts are quick to pan Eli Lil­ly's puz­zling first cut of pos­i­tive clin­i­cal da­ta for its Covid-19 an­ti­body

Eli Lilly spotlighted a success for one of 3 doses of their closely-watched Covid-19 antibody drug Wednesday morning. But analysts quickly highlighted some obvious anomalies that could come back to haunt the pharma giant as it looks for an emergency use authorization to launch marketing efforts.

The pharma giant reported that LY-CoV555, developed in collaboration with AbCellera, significantly reduced the rate of hospitalization among patients who were treated with the antibody. The drug arm of the study had a 1.7% hospitalization rate, compared to 6% in the control group, marking a 72% drop in risk.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,300+ biopharma pros reading Endpoints daily — and it's free.

Greg Friberg (File photo)

#ES­MO20: Am­gen team nails down sol­id ear­ly ev­i­dence of AMG 510’s po­ten­tial for NSCLC, un­lock­ing the door to a wave of KRAS pro­grams

The first time I sat down with Amgen’s Greg Friberg to talk about the pharma giant’s KRAS G12C program for sotorasib (AMG 510) at ASCO a little more than a year ago, there was high excitement about the first glimpse of efficacy from their Phase I study, with 5 of 10 evaluable non-small cell lung cancer patients demonstrating a response to the drug.

After decades of failure targeting KRAS, sotorasib offered the first positive look at a new approach that promised to open a door to a whole new approach by targeting a particular mutation to a big target that had remained “undruggable” for decades.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,300+ biopharma pros reading Endpoints daily — and it's free.

#ES­MO20: Out to beat Tagris­so, J&J touts 100% ORR for EGFR bis­pe­cif­ic/TKI com­bo — fu­el­ing a quick leap to PhI­II

J&J’s one-two punch on EGFR-mutant non-small cell lung cancer has turned up some promising — although decidedly early — results, fueling the idea that there’s yet room to one up on third-generation tyrosine kinase inhibitors.

Twenty out of 20 advanced NSCLC patients had a response after taking a combination of an in-house TKI dubbed lazertinib and amivantamab, a bispecific antibody targeting both EGFR and cMET engineered on partner Genmab’s platform, J&J reported at ESMO. All were treatment-naïve, and none has seen their cancer progress at a median follow-up of seven months.

#ES­MO20: Trodelvy da­ta show that Gilead­'s $21B buy­out may have been worth the big pre­mi­um

Gilead CEO Dan O’Day has been on a shopping spree. And while some analysts gawked at the biotech’s recent $21 billion Immunomedics buyout, new data released at virtual ESMO 2020 suggest the acquisition may have been worth the hefty price.

The deal, announced last weekend, will give California-based Gilead $GILD Trodelvy, which was recently approved for metastatic triple-negative breast cancer (mTNBC).

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,300+ biopharma pros reading Endpoints daily — and it's free.

#ES­MO20: It’s not just Keytru­da any­more — Mer­ck spot­lights 3 top ear­ly-stage can­cer drugs

Any $12 billion megablockbuster in the portfolio tends to overshadow everything else in the pipeline. Which is something Merck can tell you a little bit about.

Keytruda not only dominates the PD-(L)1 field, it looms over everything Merck does, to the point some analysts wonder if Merck is a one-trick pony.

There’s no shortage of Keytruda data on display at ESMO this weekend, but now the focus is shifting to the future role of new drugs and combos in maintaining that lead position for years to come. And the pharma giant has a special focus for 3 early-stage efforts where Roger Perlmutter’s oncology team is placing some big bets.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,300+ biopharma pros reading Endpoints daily — and it's free.

Exelixis CEO Michael Morrissey (file photo)

#ES­MO20: Look out Mer­ck. Bris­tol My­ers and Ex­elix­is stake out their com­bo’s claim to best-in-class sta­tus for front­line kid­ney can­cer

Now that the PD-(L)1 checkpoints are deeply entrenched in the oncology market, it’s time to welcome a wave of combination therapies — beyond chemo — looking to extend their benefit to larger numbers of patients. Bristol Myers Squibb ($BMY} and Exelixis {EXEL} are close to the front of that line.

Today at ESMO the collaborators pulled the curtain back on some stellar data for their combination of Opdivo (the PD-1) and Cabometyx (the TKI), marking a significant advance for the blockbuster Bristol Myers franchise while offering a big leg up for the team at Exelixis.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,300+ biopharma pros reading Endpoints daily — and it's free.

Donald Trump and White House chief of staff Mark Meadows, before boarding Marine One (Getty Images)

Pric­ing deal col­laps­es over Big Phar­ma's re­fusal to is­sue $100 'cash card­s' be­fore the elec­tion — re­port

Late in August, as negotiations on a pricing deal with President Trump reached a boiling point, PhRMA president Stephen Ubl sent an email update to the 34 biopharma chiefs that sit on his board. He wrote that if the industry did not agree to pay for a $100 “cash card” sent to seniors before November, White House chief of staff Mark Meadows was going to tell the news media Big Pharma was refusing to “share the savings” with the elderly — and that all of the blame for failed drug pricing negotiations would lie squarely on the industry.